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Background: SHORT syndrome is a rare autosomal dominant condition whose name is the acronym of short
stature, hyperextensibility of joints, ocular depression, Rieger anomaly and teething delay (MIM 269880).
Additionally, the patients usually present a low birth weight and height, lipodystrophy, delayed bone age, hernias,
low body mass index and a progeroid appearance.
Case presentation: In this study, we used whole-exome sequencing approaches in two patients with clinical
features of SHORT syndrome. We report the finding of a novel mutation in PIK3R1 (c.1929_1933delTGGCA; p.
Asp643Aspfs*8), as well as a recurrent mutation c.1945C > T (p.Arg649Trp) in this gene.
Conclusions: We found a novel frameshift mutation in PIK3R1 (c.1929_1933delTGGCA; p.Asp643Aspfs*8) which
consists of a deletion right before the site of substrate recognition. As a consequence, the protein lacks the position
that interacts with the phosphotyrosine residue of the substrate, resulting in the development of SHORT syndrome.
Keywords: Aging, Diabetes, Insulin, Kinase, Lipodystrophy, ProgeriaBackground
Rare syndromes are disorders that, separately, affect a
reduced number of individuals in the world. The scarcity
of patients and resources makes it very difficult to estab-
lish the molecular cause of these conditions. Despite these
drawbacks, the increasing knowledge in molecular biology
as well as the development of next-generation sequencing
methods has allowed the identification of the genetic
defects that cause some of these rare syndromes, such as
Néstor-Guillermo Progeria syndrome [1] and Kabuki
syndrome [2].
SHORT syndrome is a rare autosomal dominant
condition whose name is the acronym of short stature,
hyperextensibility of joints, ocular depression, Rieger
anomaly and teething delay (MIM 269880) [3]. Other
typical features are low birth weight, lipodystrophy,
delayed bone age, inguinal hernias, low body mass index
and a marked progeroid appearance characterized by
wrinkled skin, a triangular face with a small chin, low-set* Correspondence: clo@uniovi.es
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unless otherwise stated.posteriorly rotated ears and thin alae nasi. All these
clinical features go along with a usually normal intellect
[4]. Recently, four groups have independently reported
the finding of mutations in PIK3R1 as the primary cause
of SHORT syndrome [5-8]. In this study, we describe the
use of whole-exome sequencing technology to identify a
novel PIK3R1 mutation, as well as a point mutation
already reported in this gene, in two patients with
SHORT syndrome.
Case presentation
Methods
Exome sequencing
Written, informed consent was obtained from all subjects
or from their legal representatives, before enrollment in
the study. Both families (patient 1 and father of patient 2)
also provided a written and informed consent for the pub-
lication of the images included in this article. The study
protocol was approved by the ethics committee of the
Hospital Universitario Central de Asturias, in compliance
with the Helsinki Declaration. By the time this sequencing
analysis was carried out, the genetic cause of SHORT
syndrome was still unknown, what led us to perform an
exome sequencing analysis. For this purpose, genomicl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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a Qiagen kit according to the manufacturer’s instructions
(QIAGEN, Germany). Exome capture was performed
using a SureSelectXT Human All Exon 50 Mb Kit
(Agilent). Briefly, 3 μg of genomic DNA were sheared with
a Covaris S2 instrument and used for the construction of
a paired-end sequencing library as described in the
paired-end sequencing sample preparation protocol
provided by Illumina. Enrichment of exonic sequences
was then performed using the Sure Select Human All
Exon 50 Mb Kit (Agilent Technologies) following the
manufacturer’s instructions. Exon-enriched DNA was
pulled down using magnetic beads coated with streptavi-
din (Invitrogen), followed by washing, elution and 18
additional cycles of amplification of the captured library.
The enriched library was sequenced (2×76 bp) using a
HiSeq 2000 instrument (Illumina).Exome sequence data analysis
Sequence data were analyzed using a custom pipeline
based on the Sidrón algorithm [9,10]. Reads were mapped
to the human reference genome (GRCh37) using BWA
with the sampe option, and a BAM file was generated for
each sample using SAMtools. Optical or PCR duplicates
were removed using the rmdup option of SAMtools. A
first loose filter was used to eliminate any genomic pos-
ition where variants were extremely unlikely. Then, each
candidate variant was given an S score with Sidrón. If data
from relatives were also available, they were incorporated
at this step. Cutoff points were set depending on coverage
(cov) as follows: positions with an S value lower than
(−0.2583*cov + 2.6546) were considered homozygous.
Positions with a coverage lower than 20 were considered
heterozygous if their S value was higher than 5.807.
Positions with a coverage higher than or equal to 20 were
considered heterozygous if their S value was higher than
(0.7019*cov - 9.6348). The rules to call a variant were: a) If
a position is called as heterozygous, it is considered a
heterozygous variant; b) If the most frequently read base
is not the reference base and the position cannot be called
as heterozygous, it is considered a variant; c) If the most
frequently read base is not the reference base and the
position is classified as homozygous, it is considered a
homozygous variant. Variants present in dbSNP137 with a
minor allele frequency higher that 0.01, or present in more
than 2% of individuals of Spanish origin without previous
history of progeroid syndrome for which exome data was
available as part of the CLL-ICGC project, were discarded
as common polymorphisms. Variants potentially affecting
protein function, including non-synonymous variants,
frameshifts in the coding sequence, or variants potentially
affecting splicing, were identified with Mutandis, from the
Sidrón pipeline [9,10].Sanger sequencing
The mutations detected in the whole-exome analysis
were validated through Sanger sequencing. A fragment
of 307 bp from exon 19 of PIK3R1 was PCR-amplified
(5′-ATGGCTCCTGCACTCTTC AT-3′ and 5′-AAATC
TTTGCCCCCAAAACT-3′) and then, Sanger sequen-
cing was performed using the same primers on an ABI
PRISM 3130×l Genetic Analyzer. In patient 1, sequence
traces were analyzed with Mutation Surveyor (v.3.24,
SoftGenetics).
Results
Clinical report of two patients with SHORT syndrome
We studied 2 independent families from distant origins
with one affected member in each family (Table 1). Both
families gave their informed consent prior to their inclu-
sion in the study. The first patient studied presented
characteristics of SHORT syndrome at an early age, and
has already developed all the symptoms associated with
this syndrome so far. He was the third child from a
Spanish couple, both parents and both siblings being
healthy and with no relevant clinical family history. At
conception, his father was 48-year-old and his mother
39-year-old. He was born at terminus but with intrauter-
ine growth retardation (1,600 g at birth). The patient
was diagnosed with an atypical progeroid syndrome at
the age of 2 years and 6 months, presenting at that mo-
ment with low height (82 cm, <3rd percentile), low
weight (7,700 g, <3rd percentile), a small head circumfer-
ence (46 cm, <3rd percentile), lipodystrophy and wrin-
kled skin (especially on the hands). At 13 years of age,
he was diagnosed with diabetes and axillary acanthosis
nigricans. His facies shows a pronounced progeroid
phenotype with triangular face, ocular depression, a
small chin and thin alae nasi (Figure 1A-B). Patient 1 is
nowadays 31-year-old and he is short (153.7 cm, <3rd
percentile), very thin (28 kg, <3rd percentile) and has
hypercholesterolemia (LDL: 181 mg/dL). He has got an
extremely weak constitution and a high pitched voice.
He has also developed Rieger anomaly with Axenfeld
syndrome, as well as glaucoma and severe myopia. As
typical in SHORT syndrome, this patient also has hyper-
extensibility of joints with hip and knee osteoarthritis.
He presents normal renal and hepatic function, but he
has pulmonary hypoplasia and pulmonary valve stenosis
that has never required surgical intervention. His intel-
lectual and psychomotor development has always been
in normal range.
Patient 2 is an Italian child with a mild phenotype re-
sembling SHORT syndrome. He was born on the 38th
week of pregnancy by urgent cesarean section. At con-
ception, his father was 33-year-old and his mother 34-
year-old. At birth, he weighed 2,030 g (<3rd percentile),
measured 44.5 cm (3rd percentile) and his occipitofrontal
Table 1 Clinical features of the two analyzed patients with SHORT syndrome
Patient 1 Patient 2
General characteristics
Gender Male Male
Father age at conception 48-year-old 33-year-old
Weight at birth 1 600 g 2 030 g
Height at birth Not reported 44.5 cm
Age at assessment 2 years 6 months 6 ½months
Height at assessment 82 cm (<3rd percentile) 62 cm (<3rd percentile)
Weight at assessment 7 700 g (<3rd percentile) 4 860 g (<3rd percentile)
Head circumference at assessment 46 cm (<3rd percentile) 41.5 cm (4.5th percentile)
Facies
Progeroid appearance yes yes
Triangular face yes yes
Ocular depression yes yes
Small chin yes yes
Low-set posteriorly rotated ears no yes
Thin alae nasi yes yes
Other SHORT syndrome characteristics
Intrauterine growth retardation yes yes
Rieger anomaly yes (with Axenfeld syndrome). Glaucoma and
severe myopia
no
Lipodystrophy yes yes
Wrinkled skin yes (on the hands) yes (on the hands)
Hyperextensibility of joints yes (artrosis evolution: hip and knee) no
Inguinal hernia no no
Insulin resistance yes, with axillary acanthosis nigricans N/A
Bone age normal (osteoporosis evolution) Normal
Psychomotor development Normal Normal
Other findings
Pulmonary valve stenosis, pulmonary hypoplasia,
hypercholesterolemia
Gastro-esophageal reflux, patent anterior fontanelle,
patent foramen ovale
PIK3R1 mutation found c.1929_1933delTGGCA c.1945C > T
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obtained a 9–9 score in the APGAR test. During preg-
nancy, all screening tests were within the normal range
(fetal movement and prenatal screening tests for Down
syndrome), but from week 25th of gestation growth re-
tardation with abnormal uterine doppler was noted. Due
to intrauterine growth retardation, he was subjected to
ultrasound screening for 30 months after birth, with
normal results in all cases. He had a poor sucking reflex
for the first two months after birth, which improved
later. At 6 months of age, he was diagnosed with an
atypical progeroid syndrome, evocative of Wiedemann-
Rautenstrauch syndrome (MIM 264090), presenting by
that time low parameters for height (62 cm, <3rdpercentile), weight (4,860 g, <3rd percentile) and head
circumference (41.5 cm, 4.5th percentile). Patient 2 was
evaluated again at 6 months of age and showed lipody-
strophy with wrinkled skin on the hands (Figure 1C-F).
He also had a triangular face, ocular depression, a small
chin and thin alae nasi. Additionally, as other patients
affected with SHORT syndrome, patient 2 showed low-
set posteriorly rotated ears. Ophthalmologic examination
of this patient was normal and he did not show joint
hyperextensibility. He suffered from gastro-esophageal
reflux that was treated conservatively. He also had
patent anterior fontanelle and patent foramen ovale.
Patient 2 also had a normal intellectual and psycho-
motor development.
Figure 1 Facial appearance of patient 1 (A and B) and patient 2 (C-F). The appearance of the patients included in this study shows a clear
premature aging phenotype, detectable from the first months of life (patient 2) and striking in adulthood (patient 1).
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SHORT syndrome patients 1 and 2
Whole-exome sequencing was performed on patient 1
as well as on his mother and sister. DNA from patient’s
father was not available for study. Overall, more than
89% of the exome regions were considered callable. We
first confirmed that no variants affecting genes previ-
ously associated with progeroid syndromes were present
in the exome of the patient. After removing common
polymorphisms and variants present in mother and sister
with the same zygosity, we identified 126 variants poten-
tially affecting protein function due to the introduction of
missense, nonsense, splicing or frameshifts in the coding
regions, and not present in dbSNP137. In parallel studies,
we obtained the exome sequence of patient 2, with more
than 85% of the bases classified as callable. We identified
58,122 variants, out of which 7,711 were predicted to
affect the sequence of a protein. Furthermore, only 166 of
those variants were absent in dbSNP137 or in a local data-
base containing constitutive variants from Spanish indi-
viduals. After comparing the sets of proteins affected by
the candidate variants from both individuals, we found
that only PIK3R1 and ZNF276 were selected in both
patients. Moreover, both ZNF276 variants affect only a
minor transcript with no CCDS identifier (ENST000
00446326). Therefore, this analysis singled out PIK3R1 as
the most likely candidate driver of the disease.
The variant affecting PIK3R1 in patient 1 is a heterozy-
gous deletion of 5 nucleotides (c.1929_1933delTGGCA)
that was confirmed by Sanger sequencing and analysis
with Mutation Surveyor (Figure 2A). This indel causes the
disruption of the reading frame from position 643 of the
protein and the generation of an in-frame premature stop
codon seven residues downstream (p.Asp643Aspfs*8)
(Figure 2C). This deletion was absent in both mother
and sister of patient 1. In patient 2, we found the
variant c.1945C > T, which causes the change of arginineto tryptophan in amino acid 649 of PIK3R1 protein
(p.Arg649Trp). This mutation was also confirmed by
Sanger sequencing (Figure 2B) and was absent in the
patient’s parents. We also performed a structural model of
the protein showing the two mutations described in
this study (Figure 2D). The p.Arg649Trp (c.1945C > T)
mutation affects a position that is involved in the inter-
action with the phosphotyrosine residue of the substrate,
as shown by the proximity of this residue to the functional
group of a substrate-mimic molecule. The p.Asp643Aspfs*8
(c.1929_1933delTGGCA) mutation of patient 1 truncates
the protein right after the first alpha helix and before this
site of substrate recognition. As a result, this alpha helix
might fold properly but the resulting protein lacks the
position that interacts with the phosphotyrosine residue of
the substrate.
Discussion
We describe herein the whole-exome sequence analysis
of two patients, one Spanish and one Italian, presenting
with a progeroid phenotype whose clinical features fit a
SHORT syndrome diagnosis [4]. Both patients share
intrauterine growth retardation, short stature, low body
mass index, microcephaly, triangular face and wrinkled
skin, and the older one also presents insulin resistance,
Rieger anomaly and hyperextensibility of joints. We
show evidence of the causative role of mutations in
PIK3R1 in SHORT syndrome, adding to the recently
published papers that show mutations in this gene in
other patients with this progeroid syndrome [5-8].
The first patient described herein presents a novel
frameshift mutation in PIK3R1 that has no similarity
with any mutation reported before in the context of
SHORT syndrome. It consists of a heterozygous deletion
of 5 nucleotides from coding position 1929 to 1933 of
the PIK3R1 gene. The deletion of these 5 nucleotides
(c.1929_1933delTGGCA) elicits the disruption of the
Figure 2 Sanger sequencing of PIK3R1 (A and B), schematic representation of p85α (C) and spatial modeling of the mutated protein
(D). Electropherograms from patients 1 (A) and 2 (B) showing the corresponding mutations in PIK3R1. In patient 1, deletion of 5 nucleotides was
detected with Mutation Surveyor software. (C) Schematic representation of the protein mutated in SHORT syndrome patients. The two mutations
described in this article are outlined by a red and a yellow star. Both mutations are located in an SH2 region. In patient 1, the mutation results in
a truncated protein, whereas in patient 2, it causes an amino acid residue change. (D) Spatial localization of the mutated residues. The mutated
residues are shown on the SH2 domain contained in the PDB structure 1PIC. The truncated form resulting after mutation p.Asp643Aspfs*8 is
shown in orange. Arginine 649 is shown interacting (yellow dashed line) with the phosphate group of Acetyl-pTyr-Val-Pro-Met-Leu (blue and red
sticks). The picture was rendered with PyMOL (v.0.99rc6).
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idues downstream, leading to a truncated protein. The
absence of this deletion in his mother and sister and the
lack of any SHORT syndrome phenotype in his father
strongly suggest the occurrence of a de novo mutation in
this patient. The second patient presents a mutation that
is recurrent in other individuals with SHORT syndrome
[5-8], which consists of a de novo heterozygous C > T
transition at coding position 1945 of PIK3R1. This tran-
sition results in a change from arginine to tryptophan at
position 649 of the mature protein.
PIK3R1 encodes the subunit p85α of the PI3K kinase.
This protein kinase is part of an important metabolicpathway that induces cell growth, proliferation, protein
synthesis and apoptosis restraint, among other effects
[11]. As it has been recently published, PIK3R1 muta-
tions seem to induce the downregulation of the Akt/
mTor pathway [5-7], which could explain the small stat-
ure and weight of these patients as well as the insulin
resistance that they usually suffer from.
Conclusion
In summary, by using whole-exome capture and next-
generation sequencing, we report PIK3R1 as the gene
implicated in SHORT syndrome in two patients, further
supporting the recently published works about this
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related to this syndrome in a Spanish patient. Further-
more, the fact that PIK3R1 encodes a protein with an im-
portant role in the regulation of a metabolic pathway may
establish a new group of accelerated aging disorders,
which until now were mainly caused by alterations in the
nuclear envelope or by defects in the DNA repair systems
[12-14]. This discovery may also yield new insights into
the mechanisms of human normal aging [15], especially in
relation to metabolic alterations occurring during this
process.
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